Research progress on the treatment of advanced prostate cancer with Olaparib

被引:3
作者
Su, Yi-Xin [1 ]
Yu, Cheng-Feng [1 ]
Xue, Peng [1 ]
Li, Lin-Lu [1 ]
Xiao, Kun-Min [1 ]
Chu, Xue-Lei [1 ]
Zhu, Shi-Jie [1 ]
机构
[1] China Acad Chinese Med Sci, Wangjing Hosp, Beijing, Peoples R China
基金
中国博士后科学基金;
关键词
Olaparib; advanced prostate cancer; research progress; homologous recombination repair; synthetic lethality; DNA-REPAIR; MAMMARY-TUMORS; INHIBITOR; DAMAGE; RESISTANCE; MUTATIONS; COMBINATION; GENOMICS; THERAPY; BRCA2;
D O I
10.4149/neo_2021_210627N856
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Prostate cancer (PCa) is one of the most common malignancies in men worldwide, and metastatic castrate-resistant prostate cancer (mCRPC) has shown a poor prognosis. Although chemotherapy and androgen deprivation therapy (ADT) have improved clinical outcomes, the median survival (MS) of patients with mCRPC is still less than 2 years. With the development of poly adenosine diphosphate-ribose polymerase inhibitor (PARPi), the treatment strategy for patients with mCRPC has markedly evolved. Olaparib, a type of PARPi that can selectively induce synthetic lethality in cancer cells with homologous recombination (HR) deficiencies, was the first type of PARPi approved for treating patients with mCRPC harboring mutations in HR repair (HRR) genes. This review discusses and summarizes the latest progress on therapeutic mechanisms, monotherapy, combination therapy, and adverse events of Olaparib.
引用
收藏
页码:1132 / 1138
页数:7
相关论文
共 56 条
[1]   Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making [J].
Abida, Wassim ;
Armenia, Joshua ;
Gopalan, Anuradha ;
Brennan, Ryan ;
Walsh, Michael ;
Barron, David ;
Danila, Daniel ;
Rathkopf, Dana ;
Morris, Michael ;
Slovin, Susan ;
McLaughlin, Brigit ;
Curtis, Kristen ;
Hyman, David M. ;
Durack, Jeremy C. ;
Solomon, Stephen B. ;
Arcila, Maria E. ;
Zehir, Ahmet ;
Syed, Aijazuddin ;
Gao, Jianjiong ;
Chakravarty, Debyani ;
Vargas, Hebert Alberto ;
Robson, Mark E. ;
Vijai, Joseph ;
Offit, Kenneth ;
Donoghue, Mark T. A. ;
Abeshouse, Adam A. ;
Kundra, Ritika ;
Heins, Zachary J. ;
Penson, Alexander V. ;
Harris, Christopher ;
Taylor, Barry S. ;
Ladanyi, Marc ;
Mandelker, Diana ;
Zhang, Liying ;
Reuter, Victor E. ;
Kantoff, Philip W. ;
Solit, David B. ;
Berger, Michael F. ;
Sawyers, Charles L. ;
Schultz, Nikolaus ;
Scher, Howard I. .
JCO PRECISION ONCOLOGY, 2017, 1 :1-26
[2]   Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity [J].
Bajrami, Ilirjana ;
Frankum, Jessica R. ;
Konde, Asha ;
Miller, Rowan E. ;
Rehman, Farah L. ;
Brough, Rachel ;
Campbell, James ;
Sims, David ;
Rafiq, Rumana ;
Hooper, Sean ;
Chen, Lina ;
Kozarewa, Iwanka ;
Assiotis, Ioannis ;
Fenwick, Kerry ;
Natrajan, Rachael ;
Lord, Christopher J. ;
Ashworth, Alan .
CANCER RESEARCH, 2014, 74 (01) :287-297
[3]   Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor [J].
Barber, Louise J. ;
Sandhu, Shahneen ;
Chen, Lina ;
Campbell, James ;
Kozarewa, Iwanka ;
Fenwick, Kerry ;
Assiotis, Ioannis ;
Rodrigues, Daniel Nava ;
Reis Filho, Jorge S. ;
Moreno, Victor ;
Mateo, Joaquin ;
Molife, L. Rhoda ;
De Bono, Johann ;
Kaye, Stan ;
Lord, Christopher J. ;
Ashworth, Alan .
JOURNAL OF PATHOLOGY, 2013, 229 (03) :422-429
[4]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[5]   Targeting DNA Repair in Cancer : Beyond PARP Inhibitors [J].
Brown, Jessica S. ;
O'Carrigan, Brent ;
Jackson, Stephen P. ;
Yap, Timothy A. .
CANCER DISCOVERY, 2017, 7 (01) :20-37
[6]   Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations [J].
Carneiro, Benedito A. ;
Collier, Katharine Ann ;
Nagy, Rebecca J. ;
Pamarthy, Sahithi ;
Sagar, Vinay ;
Fairclough, Stephen ;
Odegaard, Justin ;
Lanman, Richard B. ;
Costa, Ricardo ;
Taxter, Timothy ;
Kuzel, Timothy M. ;
Fan, Alice ;
Chae, Young Kwang ;
Cristofanilli, Massimo ;
Hussain, Maha H. ;
Abdulkadir, Sarki A. ;
Giles, Francis J. .
JCO PRECISION ONCOLOGY, 2018, 2 :1-8
[7]   PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer [J].
Chabanon, Roman M. ;
Muirhead, Gareth ;
Krastev, Dragomir B. ;
Adam, Julien ;
Morel, Daphne ;
Garrido, Marlene ;
Lamb, Andrew ;
Henon, Clemence ;
Dorvault, Nicolas ;
Rouanne, Mathieu ;
Marlow, Rebecca ;
Bajrami, Ilirjana ;
Cardenosa, Marta Llorca ;
Konde, Asha ;
Besse, Benjamin ;
Ashworth, Alan ;
Pettitt, Stephen J. ;
Haider, Syed ;
Marabelle, Aurelien ;
Tutt, Andrew N. J. ;
Soria, Jean-Charles ;
Lord, Christopher J. ;
Postel-Vinay, Sophie .
JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (03) :1211-1228
[8]   NICOTINAMIDE MONONUCLEOTIDE ACTIVATION OF A NEW DNA-DEPENDENT POLYADENYLIC ACID SYNTHESIZING NUCLEAR ENZYME [J].
CHAMBON, P ;
MANDEL, P ;
WEILL, JD .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1963, 11 (01) :39-&
[9]   RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection [J].
Chapman, J. Ross ;
Barral, Patricia ;
Vannier, Jean-Baptiste ;
Borel, Valerie ;
Steger, Martin ;
Tomas-Loba, Antonia ;
Sartori, Alessandro A. ;
Adams, Ian R. ;
Batista, Facundo D. ;
Boulton, Simon J. .
MOLECULAR CELL, 2013, 49 (05) :858-871
[10]   Replication fork stability confers chemoresistance in BRCA-deficient cells [J].
Chaudhuri, Arnab Ray ;
Callen, Elsa ;
Ding, Xia ;
Gogola, Ewa ;
Duarte, Alexandra A. ;
Lee, Ji-Eun ;
Wong, Nancy ;
Lafarga, Vanessa ;
Calvo, Jennifer A. ;
Panzarino, Nicholas J. ;
John, Sam ;
Day, Amanda ;
Crespo, Anna Vidal ;
Shen, Binghui ;
Starnes, Linda M. ;
de Ruiter, Julian R. ;
Daniel, Jeremy A. ;
Konstantinopoulos, Panagiotis A. ;
Cortez, David ;
Cantor, Sharon B. ;
Fernandez-Capetillo, Oscar ;
Ge, Kai ;
Jonkers, Jos ;
Rottenberg, Sven ;
Sharan, Shyam K. ;
Nussenzweig, Andre .
NATURE, 2016, 535 (7612) :382-+